514 Participants Needed

Sovateltide for Stroke

(RESPECT-ETB Trial)

Recruiting at 19 trial locations
AG
NM
Overseen ByNeil Marwah, MD
Age: 18+
Sex: Any
Trial Phase: Phase 3
Sponsor: Pharmazz, Inc.
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Pivotal Trial (Near Approval)This treatment is in the last trial phase before FDA approval
Prior Safety DataThis treatment has passed at least one previous human trial

What You Need to Know Before You Apply

What is the purpose of this trial?

Extensive research is being conducted in search of neuroprotective agents for possible use in the acute phase of stroke and agents that can be used for neurorepair in later stages of stroke. Several trials have been conducted and are in progress using different pharmacological agents, but none of the studies involve the stimulation of ETB receptors to treat cerebral ischemic stroke. Sovateltide (IRL-1620, PMZ-1620) has been effective in animal models of cerebral ischemic stroke. Its safety and tolerability have been demonstrated in a human phase I study with 7 subjects. Clinical phase II and III results indicate that sovateltide is a novel, first-in-class, highly effective drug candidate for treating cerebral ischemic stroke. Safety and significant efficacy in improving the National Institutes of Health Stroke Scale (NIHSS), Modified Rankin scale (mRS), and Barthel index (BI) obtained in phase II and III studies in patients with cerebral ischemic stroke in India are convincing and encouraged us to investigate its safety and efficacy in cerebral ischemic stroke patients in the United States. Therefore, the plan is to conduct a phase III clinical study to evaluate the safety and efficacy of sovateltide therapy along with standard of care in patients of acute ischemic stroke.

Who Is on the Research Team?

AG

Anil Gulati, MD, PhD

Principal Investigator

Pharmazz, Inc.

Are You a Good Fit for This Trial?

This trial is for adults aged 18-80 who've had a stroke confirmed by CT or MRI, presenting within 24 hours of symptom onset with moderate to severe impairment but still conscious. They must consent to the study and be available for follow-ups. Exclusion criteria are not specified here.

Inclusion Criteria

Patient or Legally Acceptable Representative (LAR) willing to give informed consent before study procedure
My stroke was caused by a clot and confirmed by a CT or MRI, with no bleeding in the brain.
I had a stroke within the last day and my stroke severity score is between 8 and 19.
See 2 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

1-2 weeks

Treatment

Participants receive sovateltide or placebo along with standard of care. Three doses are administered as an IV bolus over one minute every 3 hours on day 1, repeated on days 3 and 6 post-randomization.

1 week
3 visits (in-person) on days 1, 3, and 6

Follow-up

Participants are monitored for safety and effectiveness after treatment, with assessments at days 30, 60, and 90 post-randomization.

12 weeks
3 visits (in-person) at days 30, 60, and 90

What Are the Treatments Tested in This Trial?

Interventions

  • Sovateltide
Trial Overview The trial tests Sovateltide's safety and effectiveness in acute ischemic stroke patients alongside standard care. It follows previous promising results from earlier phases showing improvements in stroke scales and functional outcomes.
How Is the Trial Designed?
2Treatment groups
Experimental Treatment
Active Control
Group I: Sovateltide + Standard of careExperimental Treatment1 Intervention
Group II: Normal Saline + Standard of careActive Control1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

Pharmazz, Inc.

Lead Sponsor

Trials
13
Recruited
2,100+
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security